Potential Psychiatric Uses for MDMA

Phase II trials of MDMA-assisted psychotherapy show initial safety and efficacy for treating PTSD, with potential expansion to depression and anxiety disorders. In this model, single doses of MDMA are given within a psychotherapy framework, unlike daily drug administration without therapy. This approach could benefit from accelerated regulatory pathways like the FDA Breakthrough Therapy Designation to efficiently test these novel treatments.

Study at a glance

Abstract

Phase II trials of 3,4‐methylenedioxymethamphetamine (MDMA)‐assisted psychotherapy have demonstrated initial safety and efficacy for treatment of posttraumatic stress disorder (PTSD), with potential for expansion to depression and anxiety disorders. In these trials, single doses of MDMA are administered in a model of medication‐assisted psychotherapy, differing from trials involving daily drug administration without psychotherapy. This model presents an opportunity to utilize accelerated regulatory pathways, such as the US Food and Drug Administration (FDA) Breakthrough Therapy Designation, to most effectively and expeditiously test such novel approaches.